DNA synthesis but does not affect synthesis of HBV pregenomic RNA (pgRNA). Hepatitis B virus pgRNA is detectable in the serum during NA treatment and has been proposed as a marker of HBV covalently closed circular DNA activity within the infected hepatocyte. We developed an automated assay for the quantification of serum HBV pgRNA using a dual-target real-time quantitative PCR approach on the Abbott m2000sp/rt system. We demonstrate accurate detection and quantification of serum HBV RNA. Hepatitis B virus DNA was quantified using the Abbott RealTime HBV viral load assay. We further compared serum nucleic acid levels and kinetics in HBV-positive populations. Samples included ontherapy CHB samples (n = 16), samples (n = 89) from 10 treatment naïve CHB subjects receiving 12 weeks of NA treatment with 8-week follow-up, hepatitis B surface antigen-positive blood donor samples (n = 102), and three seroconversion series from plasmapheresis donors (n = 79 samples). Conclusion: During NA treatment of CHB subjects, we observed low correlation of HBV DNA to pgRNA levels; pgRNA concentration was generally higher than HBV DNA concentrations. In contrast, when NA treatment was absent we observed serum pgRNA at concentrations that correlated to HBV DNA and were approximately 2 log lower than HBV DNA. Importantly, we observe this trend in untreated subject samples from both chronic infections and throughout seroconversion during acute infection. Results demonstrate that the presence of pgRNA in serum is part of the HBV lifecycle; constant relative detection of pgRNA and HBV DNA in the serum is suggestive of a linked mechanism for egress for HBV DNA or pgRNA containing virions. (Hepatology 2018;68:2106-2117). H epatitis B virus (HBV) is a highly infectious, hepatotropic DNA virus. More than 240 million people are chronically infected with HBV worldwide.
H epatitis B virus (HBV) is a highly infectious, hepatotropic DNA virus. More than 240 million people are chronically infected with HBV worldwide. (1, 2) Chronic HBV infection (CHB) results in high risk for progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, and/or liver-related mortality. Acute HBV infection persists to CHB in 20% to 30% of children infected between the ages of 1 and 5 (3) ; risk of persistence decreases with increased age, with chronicity occurring in 1% to 5% of cases in adults. (3, 4) During infection of the hepatocyte, HBV delivers its 3.2-kb partially double-stranded, relaxed circular DNA (rcDNA) genome to the nucleus. Here, the partial double strand is completed to form a covalently closed circular DNA minichromosome (cccDNA) that is maintained in the nucleus of the infected cell. The HBV cccDNA serves as a template for the terminally redundant 3.5-kb pregenomic RNA intermediate (pgRNA) and most mRNAs (Fig. 1) , although integrated HBV DNA fragments are also transcriptionally active. (5) During viral replication, pgRNA is transported to the cytoplasm, where it serves either as (1) a template for translation of HBV polymerase (HBV Pol) and the HBV core (HBcore) capsid protein or (2) is encapsidated by HBcore with a copy of the HBV Pol. Within the capsid, the HBV partially double-stranded rcDNA genome is synthesized from the pgRNA template with concomitant RNA degradation by HBV Pol. Previously, completion of rcDNA synthesis was considered a requirement for exit of virions containing nucleic acids from the hepatocyte to the blood stream. (6) During the clinical course of HBV infection, serum HBV DNA, HBcore, hepatitis B surface antigen (HBsAg), and the secreted hepatitis B e-antigen (HBeAg) serve as diagnostic markers for HBV infection status.
Two types of therapeutic are available for treatment of CHB: (1) long-term oral treatment with nucleos(t) ideanalogs (NAs) (e.g., lamivudine [LAM] , entecavir, tenofovir) or (2) defined duration of subcutaneously delivered pegylated interferon. Importantly, neither of the available treatment options targets the nuclear cccDNA. The HBV cccDNA persists in the hepatocytes even after establishment of immune control; as such, CHB infection cannot be fully cured. (7) In lieu of a sterilizing cure, treatment of CHB patients aims to attain a "functional" cure of CHB infection in which serum HBsAg detection is lost. (8) Nucleos(t)ide analog therapy lowers serum HBV DNA concentrations by suppressing viral replication and is linked to decreased risk of disease progression to cirrhosis, hepatocellular carcinoma, and liver-related death. (9, 10) Pegylated interferon treatment induces host immune responses and is efficacious in inducing serum HBsAg loss; however, due to the side effects associated with pegylated interferon, NA therapy is often preferred. Nucleos(t)ide analogs suppress viral replication by functioning as chain terminators, blocking HBV Pol-mediated synthesis of rcDNA from the pgRNA template within the HBcore viral particle. Treatment with NAs results in decreased HBV DNA viral loads detectable in patient serum. Notably, pgRNA synthesis from the nuclear cccDNA is not affected, and more recently, it has been appreciated that HBV RNA is detectable in CHB patient serum during NA treatment. (11) (12) (13) (14) (15) (16) (17) Recent evidence supports that the serum HBV RNA includes primarily full-length, encapsidated pgRNA, (12, 13) suggesting egress of pgRNA-containing virions occurring prior to completion of DNA synthesis. Further, observation of serum pgRNA is not limited to subjects on NA treatment: Serum pgRNA has been detected, albeit at levels lower than HBV DNA viral loads, in untreated CHB patients. (12) (13) (14) 17) Although prior to NA treatment, serum RNA levels have also been reported as undetectable. (18) The observation of pgRNA in the serum challenges the existence of a selection mechanism for rcDNA-containing virions.
Interest has grown in understanding the potential clinical relevance of circulating HBV pgRNA, namely, can serum pgRNA serve as a marker for HBV infection status? Serum HBV pgRNA has been suggested to serve as a surrogate marker for cccDNA activity in HBeAg-positive patients, (19) be predictive of HBeAg seroconversion, (14) and predict viral relapse following termination of treatment. (8) Therefore, monitoring of serum HBV pgRNA during NA treatment of CHB patients may be valuable to clinical decisions regarding treatment. The kinetics of serum HBV pgRNA relative to DNA in the absence of NA treatment and in acute stages of HBV infection is not fully understood
nor has it been reported. Our objective was to develop a robust, high-throughput method for detection and quantitation of serum HBV pgRNA in CHB patients receiving NA treatment, to facilitate evaluation of this potential clinical marker in large study populations. We used this method in conjunction with HBV DNA viral load testing to evaluate relative serum HBV DNA and pgRNA levels and kinetics in relevant patient populations: CHB patients receiving NA treatment, a set of archival longitudinal sample series from a LAM dosage study, HBV-infected blood donors, and seroconversion panels from plasmapheresis donors with acute HBV not on treatment.
Methods

SaMpleS
Human plasma or serum samples were obtained from the following sources: CHB patients for which treatment was documented (Boca Biolistics LLC, Pompano Beach, FL; Discovery Life Sciences, Los Osos, CA), blood donor plasma samples positive for HBsAg and HBV DNA (American Red Cross, Gaithersburg, MD), archived longitudinal samples from patients undergoing a 12-week course of LAM with an 8-week follow-up, (20, 21) and serial samples from plasmapheresis donors with acute HBV (North American Biological Inc., Boca Raton, FL). Samples positive for other viral infections were obtained: hepatitis E virus (HEV; Discovery Life Sciences, Los Osos, CA), human immunodeficiency virus (HIV, BioMex, Heidelberg, Germany), and hepatitis C virus (HCV; BioMex). Blood donor samples negative for HIV, HCV, and HBV were obtained for use in specificity studies (ProMedDx, Norton, MA). Institutions obtained ethics approval for the research protocols and all patients provided informed consent as per the Declaration of Helsinki.
HepatItIS B VIRUS SeRologICal MaRKeRS aND VIRal loaD
Quantitation of HBsAg and HBeAg was performed by chemiluminescent microparticle immunoassay on the Abbott ARCHITECT instrument (ARCHITECT HBsAg, ARCHITECT HBeAg; Abbott Diagnostics, Abbott Park, IL). The HBeAg antibodies (ARCHITECT Anti-HBe) and HBcore immunoglobulin M (IgM) antibodies (ARCHITECT CORE M) were detected on the ARCHITECT instrument; HBsAg antibodies were detected using AxSYM AUSAB (Abbott Diagnostics). The HBV DNA viral loads were determined using the Abbott RealTime HBV viral load assay with 0.2-mL DNA extraction protocol (Abbott Molecular, Des Plaines, IL).
DeteCtIoN oF HBV pgRNa
For detection of HBV pgRNA, primers and probes were designed to conserved regions within the 5′ end of the X gene and the 3′ end of the core gene (Fig. 1 ). Targets were independently detected: Probes were designed with 5′ FAM fluorophore and 3′ BHQ1 quencher (X target) and 5′ Q670 fluorophore and BHQ2 quencher (core target) (BioSearch, Novato, CA). Primers were synthesized by Integrated DNA Technologies (IDT, Skokie, IL). Proprietary reagents (Abbott Molecular, Des Plaines, IL) and SSIII reverse transcriptase enzyme (Sigma, St. Louis, MO) were used for the reaction mastermix. The HBV RNA was isolated using RNA-selective extraction chemistry (Abbott mSample Preparation System, Abbott Molecular) using an open-mode protocol (0.2ml_HBV_RNA_ v0.10) followed by a multiplex real-time quantitative PCR for detecting amplicons in the HBV X and core targets on the m2000 system (Abbott Molecular). Extraction and RNA amplification efficiency in each sample was validated by detecting an armored RNA internal control (Abbott Molecular) added during sample lysis. Ten microliters of eluate were added in 50 μL total reaction volume. Thermocycling conditions are as follows: 50 °C, 25 minutes; 95 °C, 10 minutes; and 50X (95 °C, 15 seconds; 62 °C, 30 seconds; 57 °C, 85 seconds). Calibration of the HBV RNA assay was established using DNA-extracted HBV DNA secondary standards (Abbott Molecular) traceable to the World Health Organization's HBV DNA standard such that a unit (U) reported for RNA in this method is equivalent to 1 IU of HBV DNA.
eValUatIoN oF aSSay peRFoRMaNCe
Assay sensitivity and linearity were evaluated on a clinical sample with high concentration of pgRNA (7.62 ± 0.13 log U/mL X target; 7.72 ± 0.14 log U/mL core target) identified in this study (sample 15, Assay specificity was evaluated in 96 HBV-negative blood donors (48 plasma and 48 serum samples). A limited study for cross-reactivity with unrelated bloodborne infections was also performed among two HIV+, two HCV+, or three HEV+ clinical samples. Matrix equivalency was tested on six CHB samples from patients receiving NA treatment that had paired plasma and serum samples available. These samples were tested in duplicate for each matrix. The RNA concentrations throughout the linear range were represented.
For confirmation of RNA selectivity (as indicated in the text), repeat RNA quantification was performed by archiving RNA eluates after DNase 1 treatment (Sigma) per the manufacturer's instructions. Briefly, deep-well plates from the m2000sp RNA extraction that had been stored at −80 °C were thawed on ice. The RNA eluate was transferred to a new 96-well plate containing 1X buffer and 1 U per reaction DNase 1; plates were incubated for 15 minutes at room temperature prior to the addition of the Stop Solution. Following heat inactivation of the enzyme at 70 ºC for 10 minutes, 10 µL of reaction volume was used as template in repeat amplification and detection on the m2000rt in the RT-qPCR pgRNA assay as described previously.
CoMpaRatoR aSSay teStINg
For a subset of samples, quantification using the described assay was compared with that of the fulllength polyadenylated HBV RNA (flRNA) target quantitated using a published method. (14) Briefly, total nucleic acids were extracted from 200 µL of plasma using a High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany) as per the manufacturer's instructions, and were eluted in 100 µL of elution buffer. As per the published protocol, poly(A) RNA provided by the kit was replaced with E. coli MRE600 ribosomal RNAs (16S and 23S; Sigma). A total of 10 µL of extracted total nucleic acids was reverse-transcribed using SuperScript III (Life Technologies, Carlsbad, CA) and 2.5 µM 3′ RACElong primer in a 20 µL reaction at 50 ºC for 1 hour following the enzyme manufacturer's protocols. A total of 2 µL of complementary DNA was then amplified and detected by using the FastStart Universal Probe Master (Roche Diagnostics) in a 40-µL reaction containing 900 nM HBV-x-long forward primer, 900 nM anchored-long reverse primer, and 500 nM HBV-xlong FAM probe. Following an activation step of 95 ºC for 10 minutes, 45 cycles of 95 ºC for 5 seconds and 60 ºC for 30 seconds were run on a CFX96 Touch Real-Time PCR System (Bio-Rad, Hercules, CA). For calibration, an amplicon (ATCCTGCAACTT  TTTCACCTCTGCCTAATCATCTCTTGTA  CATGTCCCACTTTTCAAGCCTCCAAGCTG  TGCCTTGGATGGCTTTGGGGCATGGACAT  TGACCCT TATAAAGAAT T TGGAGCT TC  AAAAAAAAAAAAAAAAAGTGAGTAGC GATAGCGTGGTTGTGGAGT based on the sequence of EU366129, genotype A1) flanked with the primer pair of HBV-x-long/anchored-long was synthesized and cloned into plasmid pBluescript II KS at the XbaI/EcoRI sites (GenScript, Piscataway, NJ). Plasmid DNA was linearized with HindIII (Life Technologies) and purified by passing through a NucAway spin column (Life Technologies) hydrated in water. The concentration of the purified plasmid DNA was then determined by measuring the A260 (DU800 Beckman Spectrophotometer), and the copy number was calculated. A dilution series of this plasmid DNA calibrator was used to generate a standard curve for determining the quantitation of sample flRNA.
StatIStICal aNalySIS
Statistical analyses were performed in Microsoft Office Excel or JMP (11.2.0) unless otherwise noted.
Results
aSSay DeSIgN aND pgRNa DeteCtIoN
The HBV pgRNA assay was designed for duplexed detection of two targets in the 5′ and 3′ end of the full-length pgRNA, respectively (Fig. 1) . In this study, we describe pgRNA testing results from HBV-positive samples from diverse subject populations, including both NA-treated and untreated samples. Data from assay linearity studies demonstrated that amplification efficiencies between the two targets were comparable: −3.497 (X) and −3.499 (core) (Supporting Fig. S2B ). To evaluate relative target detection, we compared X and core quantitation in all positive samples (n = 159) and observed good correlation (R 2 = 0.9804) ( Fig. 2A) . Furthermore, Bland Altman analysis shows a 95% confidence agreement interval spanning a narrow range (0.211 to −0.647 log U/mL difference between the two targets) with a −0.218 log U/mL bias favoring core (Fig. 2B) . (22) Thus, results for X and core target detection among the samples tested herein were comparable, supporting that the serum RNA detected is primarily full-length pgRNA.
Testing was also performed to confirm selectivity for RNA. The remaining volumes of RNA eluates (n = 127) were subsequently treated with DNase 1 and requantitated in the pgRNA assay (some RNA eluates were not available for testing) (Supporting Fig. S1A ). Correlation of pgRNA results obtained using the nominal pgRNA protocol and from the same eluates after DNase digest confirmed the nominal result (R 2 = 0.982 for X; R 2 = 0.966 for core) (Supporting Fig. S1A ), supporting that quantitative values represent RNA alone.
CoMpaRatoR teStINg oF pgRNa ReSUltS
To further evaluate assay performance, clinical samples representing both on-treatment (n = 12) and untreated (n = 5) HBV+ subjects were quantitated using a previously published method for detection of serum HBV RNA. (14) Regression analyses demonstrated good correlation between the full-length RNA target in the comparator assay and pgRNA assay results for both X (R 2 = 0.93) and core (R 2 = 0.92) targets, albeit sensitivity was higher using the pgRNA method described herein (Fig. 3) .
aSSay peRFoRMaNCe
The limit of detection (LOD, 95% detection) for each of the assay targets was extrapolated through Probit analyses to be 1.65 log U/mL (X) and 1.67 log U/mL (core); limits of quantitation (LOQ , 20% coefficient of variation) were equivalent to the LOD for the X target (1.65 log U/mL) and 1.81 log U/mL for the core target (Supporting Table S1 ). R 2 values for X (0.9901) and core (0.9879) targets indicated linearity over the tested range ( Supporting Fig. S1 ); low SDs were observed for replicates within and between runs (Supporting Table S2 ). Six clinical samples with both plasma and serum volume available were tested in duplicate to assess matrix equivalency. The low observed SD between replicates further demonstrates assay repeatability; low SD between sample matrices demonstrates lack of matrix bias (Supporting Table S3 ). Assay specificity was confirmed by observation of no-detection 96 HBV-negative blood donors, demonstrating 100% specificity (95% confidence interval [CI]: 96.23%-100% based on binomial distribution). Furthermore, no cross-reactivity was observed in HEV-, HIV-, or HCV-positive samples tested.
SeRUM pgRNa IS HIgHeR tHaN HBV DNa IN MoSt CHB patIeNtS ReCeIVINg Na tReatMeNt
Samples from 16 CHB patients receiving either entecavir or tenofovir were tested for HBsAg, HBV DNA viral load, pgRNA, and HBeAg (Fig. 4) . All samples had detectable HBsAg (Fig. 4) . The HBV DNA viral loads ranged from undetectable (samples 1, 2) to 8.6 log IU/mL (sample 16). The HBV pgRNA was detected in all samples.
Correlations between HBV DNA and pgRNA target concentrations were low (X R 2 = 0.4963; core R 2 = 0.5434; Fig. 6A ), although samples with low pgRNA (< LOQ, samples 2 and 4) also had either undetectable or low (29 IU/mL) DNA viral loads. Of the 14 pgRNA results greater than the LOQ , 13 samples had pgRNA concentrations greater than the DNA viral load, consistent with suppression of HBV DNA synthesis. The average difference (very low to average pgRNA) among these was −2.45 ± 1.13 log. The greatest observed difference was sample 7, with 5 log greater average pgRNA relative to the DNA viral load.
FIg. 3.
Regression analysis of pgRNA results and concentrations measured using a RACE method shows agreement albeit greater sensitivity in the pgRNA assay. Eleven samples were reactive for HBeAg; of the five HBeAg nonreactive samples, four had sufficient volume remaining to allow testing for anti-HBe. All HBeAg nonreactive samples that were tested demonstrated HBeAg seroconversion (Fig. 4) . Overall, HBeAg nonreactive samples tended to have lower levels of HBV DNA, consistent with the inactive CHB phase of infection. (23, 24) The pgRNA concentrations were also lower in these samples relative to the HBeAg positive subjects (Supporting Fig. S3 ). Only 11 of 16 samples had information available on the duration of NA treatment (average of 1.6 years; maximum of 6 years; minimum of 3 weeks). Duration of treatment and the serum HBV DNA or pgRNA (X or core) quantitation showed no correlation (data not shown), although the sample size and distribution of treatment durations were limiting.
SeRUM HBV NUCleIC aCID KINetICS IN loNgItUDINal SaMpleS FRoM CHB patIeNtS ReCeIVINg a 12-WeeK CoURSe oF laM tReatMeNt
Archival longitudinal samples from 10 treatment-naïve CHB subjects who received a 12-week course of LAM with 8-week follow-up (20) were tested for both HBV DNA viral load and pgRNA. Limiting sample volumes affected testing in some instances (e.g., baseline DNA viral loads were not obtained for patients 3 and 6; and for patient 8, the week 16 and week 20 samples were diluted 1:100 for pgRNA testing). Previous data for HBeAg and alanine aminotransferase (ALT) was available (Fig. 5) . (20) Subjects received either 300 mg per day (n = 4), 100 mg per day (n = 4), or 25 mg per day (n = 2) LAM. Currently, 100 mg per day is the approved dosage for LAM. (24) Primary nonresponse to NA therapy is defined by the European Association for the Study of the Liver (EASL) as less than 1 log IU/mL decrease in HBV DNA viral load after 12 weeks of treatment. (25) Where baseline and week 12 DNA viral load data were available (note: week 8 result was used for patient 5), the average decrease was 4.51 ± 0.27 log IU/mL for the 300 mg per day cohort and 3.99 ± 1.36 log IU/mL for the 100 mg per day cohort. Variable HBV DNA response was observed between the two subjects receiving 25 mg per day: Subject 10 had a 2.32 log IU/mL decrease, whereas the viral load of subject 9 decreased by only 0.59 log IU/mL.
Among the nine subjects demonstrating viral load decrease consistent with treatment response, pgRNA levels remained static in seven subjects, whereas two subjects showed pgRNA concentration decline (subject 7 and 8). In one of these patients, pgRNA and DNA viral load decline continued during the 8-week follow-up, and HBeAg seroconversion was observed. The other patient with pgRNA decline showed both pgRNA and DNA viral load rebound during the 8-week follow-up. Notably, in the series in which both baseline and week 16 or 20 data were available (patients 2, 4, 5, and 10), we observed that relative serum nucleic acid levels returned to approximate baseline kinetics during follow-up after treatment cessation.
ReSUltS IN INDIVIDUal SaMpleS FRoM HBV+ BlooD DoNoRS
Serum HBV nucleic acid levels were then evaluated in untreated subject samples. A total of 102 samples from HIV-negative and HCV-negative, HBsAgpositive blood donors with detectable HBV DNA were tested for pgRNA. The HBV DNA viral loads within this population ranged from 1.13 to 8.42 log IU/mL. We observed pgRNA in 92 of 102 samples; concentrations ranged from undetectable to 7.8 log U/mL. In pgRNA positive samples, HBV DNA viral loads were consistently higher than pgRNA levels, and we noted correlation of nucleic acid levels was higher than observed in the on-treatment cohort (X R 2 = 0.7756; core R 2 = 0.8198; Fig. 6B ). Furthermore, the average observed difference (DNA viral loadaverage pgRNA) was consistent at 1.70 ± 0.71 log; the maximum observed difference was HBV DNA being greater than pgRNA by 3.13 log. Of the 10 samples without detectable pgRNA, all were HBeAg-negative, anti-HBeAg positive, and negative for HBcore IgM. Among these samples, the average HBV DNA viral load was 2.41 ± 0.64 log IU/mL; the highest viral load was 3.88 log IU/mL.
We compared serum HBV nucleic acid levels in HBeAg reactive (n = 18) to nonreactive (n = 84) cohorts. The HBeAg-reactive subjects generally have elevated HBV DNA viral load compared with HBeAg-nonreactive subjects. (23, 24) Results for the 102 blood donors in this study were consistent with this observation ( Supporting Fig. S3) ; and furthermore, pgRNA concentrations for both targets were observed to be significantly lower in the HBeAg nonreactive population (Supporting Fig. S3 , Supporting Table S4 ).
The study population was also stratified as acute or chronic infection according to the Centers for Disease Control case definitions. (26, 27) Most samples (n = 100) had results consistent with CHB (anti-HBcAg IgM negative and HBV DNA/HBsAg positive); only two samples showed reactivity for core antigen IgM, consistent with acute HBV infection (1 HBcAg IgM reactive; 1 HBcAg IgM grayzone reactive). Serum pgRNA was detected in the two samples with serologic profiles, consistent with acute infection; the difference relative to DNA viral load was lower relative to the chronic samples tested (0.81 ± 0.19 log).
SeRUM HBV NUCleIC aCID KINetICS DURINg aCUte HBV INFeCtIoN
We noted that two blood donor samples with reactivity to HBV core IgM (consistent with acute infection) had detectable pgRNA. To gain further understanding of serum pgRNA levels in acute samples, we opted to test for pgRNA in three longitudinal sample series from untreated patients with acute HBV infection to evaluate serum HBV nucleic acid kinetics.
These samples represent acute infections that either spontaneously resolved with HBsAg seroconversion (13867-3482 and 1807-3463) or persisted toward chronicity, defined as more than 6 months with HBsAg positive results 0994-3457) (Fig. 7) . In each case, serum pgRNA was detectable throughout the viremic phase. The HBV DNA viral load of series 13867-3482 did not exceed 6 log IU/mL; the maximum concentration of pgRNA was 3.54 log U/mL. The average difference (DNA viral load -average pgRNA) in this series was 2.33 ± 0.53 log (maximum 2.92; minimum 1.51). In   FIg. 5 . Testing results for 10 CHB patients receiving a 12-week course of LAM (yellow line) with 8-week follow-up. For each subject, the top graph shows the results for molecular testing with DNA (log IU/mL) as a black line, X target pgRNA as a blue line, and core pgRNA as a red line; the bottom graph gives ALT (green line) and HBeAg (orange line) testing results. Note the different y axis for the HBeAg for subject 4. The dashed lines in the pgRNA target plots for the subject indicate trend in results; samples at week 16 and week 20 were diluted 1:100 due to limiting volume and no pgRNA was detectable.
series 1807-3463, the HBV DNA viral load reached 9.23 log IU/mL; the maximum pgRNA concentration was 7.00 log U/mL. The average difference (DNA viral load -average pgRNA) was 2.58 ± 0.30 log (maximum 3.04; minimum 1.83). Finally, in the series in which infection persisted 0994-3457), the maximum DNA viral load was 9.38 log IU/mL and the maximum pgRNA concentration was 8.14 log U/mL. The average difference (DNA viral load -average pgRNA) in this series was 1.85 ± 0.31 (maximum 2.62; minimum 1.34).
Overall, we observed a consistent level of pgRNA relative to DNA viral load in samples from acute infection that were not suppressed for HBV DNA synthesis (Fig. 7) . Correlation of HBV and pgRNA targets within each acute infection series was observed (Fig. 7 , right) and comparable to those of the blood donor cohort (Fig. 6) . When serum nucleic acid levels were compared between acute and chronic (after 6 months of HBsAg positivity) samples, there was no appreciable difference in correlation or relative levels (not shown).
Discussion
HBV RNA in patient serum was first reported nearly 2 decades ago. (28) It has recently been shown that this serum RNA is protected from exogenous RNases, (13) copurifies with the HBcore capsid protein, (13) copurifies with HBV DNA and HBcore in a sucrose gradient, (12, 17) and is primarily full length (as shown by northern blot), (12) supporting that the RNA detected in serum is encapsidated pgRNA. We developed a robust, high-throughput research assay for the detection of HBV RNA in plasma and serum samples. Our results show that comparable quantitation of duplexed X and core targets are consistent with the analyte being the full-length pgRNA target ( Figs. 1 and 2) . Quantitation of pgRNA is traceable to the WHO HBV DNA standard such that 1 U of pgRNA is equivalent to 1 IU of HBV DNA, facilitating comparison of relative serum HBV nucleic acid levels.
We evaluated HBV nucleic acid levels in several HBV subject populations. Consistent with previous findings, we observed that HBV DNA viral loads in most samples from CHB patients receiving NA therapy were lower than (and had low correlation to) pgRNA concentrations. In contrast, we observed that HBV DNA viral loads in samples from untreated CHB patients were greater than (but had higher correlation to) pgRNA concentrations. We further report that the differential between serum HBV DNA and pgRNA in untreated CHB patients was consistently about 2 log (1.90 ± 0.77 log). Within the untreated cohort, 10 samples with low DNA viral loads (average 2.41 ± 0.64 log IU/mL) did not have detectable RNA; our results support that these samples likely contained pgRNA below the assay LODs (1.65 log U/mL [X] and 1.67 log U/mL [core]). Corroborating our findings, Wang et al. showed that 11 treatment-naïve CHB patients had serum HBV DNA levels that were approximately 1 to 2 log higher than pgRNA.
(12) However, we previously noted one example in which the baseline samples (prior to NA treatment) were reported to have undetectable serum RNA despite elevated DNA viral loads. (18) This may be due to limitations of the methodology used when samples contain DNA concentrations that are higher than RNA. Our data further show that both HBV DNA and pgRNA levels were lower in HBeAgnonreactive samples compared with HBeAg-reactive samples, regardless of treatment status (Supporting Fig. S3, Supporting Table S4 ).
Little has been reported regarding serum pgRNA levels during acute HBV infection, albeit detection has previously been observed in a cohort that included 19 subjects with acute HBV. (29) Herein, we observed detectable serum pgRNA in two blood donors with reactivity for HBcore IgM and, importantly, observed similar HBV DNA and pgRNA kinetics during acute infection in seroconversion panels from three plasmapheresis donors. In panels from two of these donors who resolved acute HBV infection, the peak DNA levels were 5.53 and 9.23 log IU/mL. The HBV DNA correlated with pgRNA levels over time and the mean differences between DNA and pgRNA for the respective series were 2.33 ± 0.53 and 2.58 ± 0.30 log, with DNA being higher. This trend was also observed in an acute case in which the patient progressed toward chronicity, where the maximum DNA level was 9.38 log IU/mL and the mean difference between DNA and pgRNA was 1.85 ± 0.31 log. The relative pgRNA and DNA levels in this series did not differ substantially from those that resolved infection, nor did they differ before and after 6 months of HBV positive testing (after which the case definition would be considered chronic). (27) Thus, overall we found that in the absence of treatment pgRNA is detectable in the serum at a consistent level relative to HBV DNA in both chronic and acute HBV infection (even though we note that results in acute infections should be verified in a larger sample population). This suggests a model in which the egress of both rcDNA-containing and pgRNA-containing viral particles from the infected hepatocyte consistently occurs during HBV infection and may be mechanistically linked. The presence of pgRNA in the serum demonstrates that selectivity for rcDNA-containing virions is not absolute.
Nucleos(t)ide analog treatment disrupts the relative levels of serum pgRNA and DNA viral loads, resulting in detection of serum pgRNA at levels greater than DNA (Fig. 8) . As seen in this study for treatment-naïve CHB patients undergoing a 12-week course of LAM, following removal of treatment, viral loads rebounded and relative nucleic acid levels returned to baseline kinetics (Fig. 5 ). Alternatively, with prolonged DNA suppression due to NA treatment, decreasing cccDNA activity would likely manifest as decreased detection of serum pgRNA (Fig. 8) . Understanding the coupled relationship between serum HBV DNA and pgRNA may allow improved understanding of patient response to NA therapy. For example, in the absence of baseline data, we can infer that sample 16 from the on-treatment cohort is not effectively suppressed for DNA synthesis at the time of sample draw, because the serum HBV DNA viral load is elevated relative to pgRNA, consistent with untreated samples (HBV DNA -average pgRNA = 1.49 log) (Fig. 4 ).
An important consideration for the molecular detection of serum HBV RNA by real-time quantitative PCR is the potential presence of residual HBV DNA in the sample. The ability to detect residual DNA and flag affected results is a necessity. We developed an automated, high-throughput assay for the detection of HBV pgRNA; we report high correlation between the nominal method and deoxyribonuclease-treated sample results herein (Supporting Fig. S1 ). Nucleos(t) ide analog treatment is generally continued long-term for CHB patients. However, according to the treatment guidelines put forth by the American Association for the Study of Liver Diseases, (24) the European Association for the Study of the Liver (EASL) (23) and the Asian Pacific Association for the Study of the Liver, (30) NA treatment may be terminated in noncirrhotic HBeAgnegative patients who achieve HBsAg loss and/or seroconversion or, in noncirrhotic HBeAg-positive patients, HBeAg seroconversion with undetectable HBV DNA for more than 12 months. Despite this, life-long monitoring at regular intervals is recommended to detect relapses. (24, 31) Pregenomic RNA and DNA kinetics may provide an additional way to stratify treatment response. Subsequent studies will focus on understanding serum pgRNA kinetics relative to other relevant HBV makers with the aim of defining the utility of HBV pgRNA as a marker during NA treatment in clinical infections and assessment of altered treatment regimens.
